Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

17.39
+0.11000.64%
Post-market: 17.450.0600+0.35%19:30 EDT
Volume:520.04K
Turnover:9.06M
Market Cap:1.06B
PE:-10.58
High:17.70
Open:17.40
Low:17.21
Close:17.28
52wk High:35.34
52wk Low:12.12
Shares:61.14M
Float Shares:49.82M
Volume Ratio:0.72
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6429
EPS(LYR):-1.8336
ROE:-10.70%
ROA:-8.80%
PB:1.15
PE(LYR):-9.48

Loading ...

Janux Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 08

Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating

MT Newswires Live
·
May 08

Janux Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
May 08

Janux Therapeutics price target lowered to $26 from $30 at Piper Sandler

TIPRANKS
·
May 08

Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Janux Therapeutics Inc (JANX) and Progyny (PGNY)

TIPRANKS
·
May 08

Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14

TIPRANKS
·
May 08

Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward

TIPRANKS
·
May 08

Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Janux Therapeutics Q1 EPS $(0.39) Beats $(0.53) Estimate, Sales $3.733M Miss $3.833M Estimate

Benzinga Earnings
·
May 08

Janux Q1 FY26 net loss widens to $24.4 million; R&D expenses rise to $26.8 million

Reuters
·
May 08

BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.39

Reuters
·
May 08

Janux Therapeutics Q1 Net Income USD -24.361 Million

THOMSON REUTERS
·
May 08

Janux Therapeutics Q1 Operating Expenses USD 37.946 Million

THOMSON REUTERS
·
May 08

Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA)

TIPRANKS
·
Apr 29

Janux Therapeutics Adjusts Board Class Structure for Director

TIPRANKS
·
Apr 29

Janux reclassifies Eric Dobmeier as Class II director, keeps him on compensation committee

Reuters
·
Apr 29

Janux Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 29

Janux Therapeutics Is Maintained at Buy by Jones Trading

Dow Jones
·
Apr 29